Liraglutide is a GLP‐1 receptor agonist already approved for the treatment of diabetes and has undergone phase‐II trials showing improved liver histology in patients with NASH (LEAN, NCT01237119). Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.